February 4, 2022
Life Sciences
  • Eli Lilly and Co. pushed back its timeline to ask regulators to grant accelerated approval to its experimental Alzheimer’s disease drug. The drugmakers said approval would have little impact on its business this year given Medicare officials’ decision to limit coverage, which was prompted by Biogen Inc.’s controversial Alzheimer’s treatment. Eli Lilly now plans to complete the application sometime later this year. (Article here)